- Welcome to Specialised Therapeutics
-
SE Asia (HQ)
+65 3158 9940
-
Australia
1300 798 820
-
New Zealand
+64 9801 0299
Our History – Horizontal
- ST Founded
- ST - Abraxis Bioscience Partnership
- ST-Helsinn Healthcare Partnership
- ABRAXANE Reimbursed
- ALOXI Reimbursed
- Photonamic GmbH and co Partnership
- Genomic Health Partnership
- Ariad Pharmaceuticals Partnership
- ABRAXANE® reimbursed for metastatic pancreatic cancer (mPc)
- AKYNZEO Acquired
-
-
February 2008 - ST – Abraxis Bioscience Partnership
February 2008ST acquires exclusive Australian rights to market foundation product ABRAXANE® (nanoparticle-albumin bound paclitaxel) -
January 2009 - ST-Helsinn Healthcare Partnership
January 2009ST partners with privately-owned Swiss pharma company Helsinn Healthcare, acquiring exclusive rights to anti-nausea drug ALOXI® (palonesetron) in Australia and NZ -
May 2009 - ABRAXANE® Reimbursed
May 2009ABRAXANE® (nanoparticle albumin-bound paclitaxel) reimbursed in Australia for metastatic breast cancer (mBc) -
November 2010 - ALOXI® Reimbursed
November 2010ST achieves PBS reimbursement for ALOXI® (palonosetron) -
January 2012 - Photonamic GmbH and co Partnership
January 2012ST acquires exclusive rights to market brain tumour visualisation technology GLIOLAN® (animolivulenic acid hcl) in Australia, New Zealand -
January 2014 - Genomic Health Partnership
January 2014ST partners with US company Genomic Health to market the Oncotype DX Breast Recurrence Score® test -
January 2014 - Ariad Pharmaceuticals Partnership
January 2014US-based Ariad Pharmaceuticals grants ST exclusive rights to market ICLUSIG® (ponatinib) in Australia, NZ -
November 2014 - ABRAXANE® reimbursed for metastatic pancreatic cancer (mPc)
November 2014ST achieves a further PBS listing for ABRAXANE® in metastatic pancreatic cancer -
May 2015 - AKYNZEO® Acquired
May 2015ST acquires AKYNZEO® (netupitant) under exclusive license from Helsinn Healthcare